HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $32 price target.
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell
• RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022.
• Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Alkermes Earnings Preview
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here’s what investors need…
JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $33 to $29.
Piper Sandler Upgrades Alkermes to Overweight, Raises Price Target to $30
Piper Sandler analyst David Amsellem upgrades Alkermes (NASDAQ:ALKS) from Neutral to Overweight and raises the price target from $26 to $30.
Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates
Change Healthcare Inc. (NASDAQ: CHNG) reported first-quarter fiscal 2023 adjusted earnings per share (ETF:EPS) of 38 cents, which missed the Zacks Consensus Estimate of 39 cents by 2.6%. The bottom line declined 7.3% on a year-over-year basis.
Mizuho Maintains Buy on Alkermes, Lowers Price Target to $34
Mizuho analyst Vamil Divan maintains Alkermes (NASDAQ:ALKS) with a Buy and lowers the price target from $36 to $34.
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.